文献速递消化道肿瘤与早癌消化内镜

首次与重复粪便免疫化学检测筛查中结直肠癌的分期分布

Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-08-22

研究基于荷兰国家筛查数据库2014至2018年数据,比较首次与第二次粪便免疫化学检测(FIT)筛查中检出结直肠癌(CRC)的分期分布,并分析不同FIT截断值下的假想检出率与分期。首次和第二次筛查分别检出15755例和3304例CRC,两者I-II期比例相近(66.5% vs 67.7%;相对危险度1.02;95%CI 1.00-1.05)。将FIT截断值从47 μg血红蛋白/g粪便提高至250 μg时,首次和第二次筛查检出CRC分别减少88.3%和79.0%,但多数检出CRC(63%-64%)仍为I-II期。

要点

  • 首次与第二次FIT筛查检出的CRC中I-II期比例无显著差异(66.5% vs 67.7%;相对危险度1.02;95%CI 1.00-1.05)。
  • FIT截断值从47 μg提高至250 μg血红蛋白/g粪便时,首次筛查检出CRC减少88.3%,第二次筛查减少79.0%。
  • 即使提高FIT截断值,多数检出CRC(63%-64%)仍为I-II期。

核心结论

  • 基于FIT的筛查可有效使CRC分期前移,且在重复筛查中同样有效。
  • 提高FIT截断值对检出CRC分期分布的影响有限,但大幅影响CRC检出,因此保持低截断值很重要。

研究设计与样本

  • 研究获取2014至2018年荷兰国家筛查数据库中FIT阳性(截断值47 μg血红蛋白/g粪便)的首次或第二次(即重复)筛查参与者数据。
  • 通过链接荷兰癌症登记获取肿瘤特征,比较首次与第二次筛查检出CRC的诊断分期(I-II期 vs III-IV期),并分析FIT截断值提高至250 μg血红蛋白/g粪便时的假想检出率与分期分布。

主要发现

  • 首次和第二次筛查分别检出15755例和3304例CRC。
  • 首次与第二次筛查检出CRC为I-II期的可能性相同(66.5% vs 67.7%;相对危险度1.02;95%CI 1.00-1.05)。
  • FIT截断值从47 μg提高至250 μg血红蛋白/g粪便的假想情景下,首次筛查检出CRC减少88.3%,第二次筛查减少79.0%。
  • 即使在此假想情景下,多数检出CRC(63%-64%)仍为I-II期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: For colorectal cancer (CRC) screening to be effective, it is important that screen-detected cancers are found at an early stage. Studies on stage distribution of screen-detected CRC at repeat screening of large population-based fecal immunochemical test (FIT)-based screening programs and the impact of FIT cut-off values on staging currently are lacking. METHODS: We obtained data for FIT-positive participants (FIT cut-off, 47 μg hemoglobin/g feces) at their first or second (ie, repeat) screening from the Dutch National Screening Database from 2014 to 2018. Tumor characteristics were acquired through linkage with The Netherlands Cancer Registry. We compared stage at diagnosis (I-II vs III-IV) of CRCs detected at a first or second screening. In addition, we analyzed the hypothetical yield and stage distribution of CRC for different FIT cut-off values up to 250 μg hemoglobin/g feces. RESULTS: At the first and second screenings, respectively, 15,755 and 3304 CRCs were detected. CRCs detected at the first or second screening were equally likely to be stages I to II (66.5% vs 67.7%; relative risk, 1.02; 95% CI, 1.00-1.05). A hypothetical increase of the FIT cut-off value from 47 μg to 250 μg resulted in a reduction of detected CRCs by 88.3% and 79.0% at the first or second screening, respectively. Even then, the majority of detected CRCs (63%-64%) still would be diagnosed at stages I to II. CONCLUSIONS: FIT-based screening is effective in downstaging CRC, and also at repeat screening. Increasingly, the FIT cut-off level has a limited impact on the stage distribution of detected CRCs, although it greatly affects CRC detection and thus is important to keep low.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kooyker A, de Jonge L, Toes-Zoutendijk E, et al. Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening. Clin Gastroenterol Hepatol. 2023. PMID: 37619823. doi:10.1016/j.cgh.2023.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。